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A B S T R A C T
Background: Direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA) prevent thromboembolism in
atrial fibrillation (AF). DOAC have a fixed dosing regimen and obviate INR monitoring. Therefore, DOAC pre-
sumably affect quality of life (QoL) less than VKA. However, some VKA users appreciate the monitoring. A high
time in the therapeutic range (TTR) leads to a lower impact on QoL. We assessed the influence of switching from
well-controlled VKA to a DOAC on QoL.
Methods: In the GAInN study, 241 patients with AF, a TTR≥ 70%, and neither bleeding nor thrombosis while on
VKA were randomised to switching to DOAC (n=121) or continuing VKA (n=120). Health-related (SF-36) and
anticoagulation-related QoL (PACT-Q) was assessed at baseline and after six and twelve months of follow-up.
Results and Conclusion.
SF-36 development did not differ between groups. After one year, average PACT-Q Convenience improvement
was 2.5 (0.3–4.7) higher on DOAC. DOAC users were 6percentage points (95%CI -4–16) more likely to im-
prove> 5 points on Convenience; 22 pp. (95%CI 1–43) in patients who scored<95/100 at baseline. The
probability to meaningfully improve on PACT-Q Satisfaction was 12 pp. (95%CI 0–25) higher on DOAC.
However, 5 (4.1%) and 4 (3.3%) DOAC users resumed VKA because of side-effects and patient preference.
Switching from well-controlled VKA to DOAC for AF leads to a higher probability of improved PACT-Q con-
venience and satisfaction, but also to a higher risk of side-effects. Arguably only patients who are not satisfied
with VKA should switch, because they have more to gain by switching.
1. Introduction
Atrial fibrillation (AF) is a cardiac arrhythmia that will affect one in
five persons during their lifetime [1]. A feared complication of atrial
fibrillation is stroke, with a debilitating impact on quality of life [2].
Although anticoagulation reduces the risk of stroke, its impact on
quality of life is not just positive: anticoagulation aggravates bleedings
that, in turn, impair quality of life [3,4].
Two types of anticoagulants are commonly prescribed in AF: vi-
tamin K antagonists (VKAs) and direct oral anticoagulants (DOACs).
VKAs have been prescribed for decades, and are used by hundreds of
thousands of patients in the Netherlands alone. Because of its small
therapeutic window, VKA therapy needs to be regularly monitored, and
the dose titrated, to maintain an anticoagulation intensity (interna-
tional normalised ratio, INR) within the therapeutic range. This can be
cumbersome and could affect the quality of life of its users. DOACs have
been introduced as a more convenient alternative for VKAs. They are
non-inferior to VKAs for stroke prevention in AF [5], have a fixed
dosing regimen, and do not require INR monitoring. Therefore, DOAC
could have a favourable effect on quality of life.
However, vitamin K antagonists only have a limited effect on
quality of life. After the first three months of therapy, quality of life is
restored to that of the general population [4]. Furthermore, patients
who use VKA with a high time within the therapeutic range have lower
bleeding and thrombotic risks [6] and require less frequent INR mon-
itoring than patients with poor VKA control. At the same time, VKA
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may also come with an advantage over DOAC with respect to quality of
life, as many patients find the INR monitoring reassuring.
All other things being equal, impact on quality of life could be de-
cisive in the choice for a particular anticoagulant. We aimed to establish
whether switching to a DOAC would improve quality of life in the
subgroup of patients who were previously well-controlled on VKA.
2. Methods
2.1. Trial aims and design
The Good Anticoagulation In the north of the Netherlands (GAInN)
study explored bleeding and thrombotic risks of continuing VKA or
switching to a DOAC in patients with atrial fibrillation who were cur-
rently well-controlled on VKA. As part of this study, we assessed quality
of life.
This study was registered in the Netherlands Trial Registry
(NTR4770) and the EU Clinical Trials Register (2013-004805-14), and
was approved by the local research ethics committee at the University
Medical Center Groningen (METc UMCG 2014/002).
2.2. Participants and study procedures
Records of patients who satisfied the inclusion criteria were ex-
tracted by Certe Trombosedienst, a large, first-line, thrombosis service
for the northern provinces of the Netherlands. Inclusion criteria were:
patients aged 18 and above who were treated with VKA for non-valv-
ular atrial fibrillation and managed by Certe Trombosedienst; a
minimum duration of treatment of six months at the time of selection; a
time within the therapeutic range (INR 2.0–3.5) of at least 70% over the
previous four months. From all consecutive patients, we randomly se-
lected eligible subjects who were sent patient information and contact
information to plan an information visit if they were interested.
After the patient had provided written informed consent, eligibility
was re-checked. Exclusion criteria were: a thrombo-embolic event or
major bleeding ever while on VKA; indication for anticoagulation other
than atrial fibrillation; contra-indication to receive any kind of DOAC; a
life expectancy< 1 year. We aimed to include 240 patients to obtain a
reliable estimate of the effect on clinical outcomes; sample size calcu-
lation was based on the primary objective of the trial and not on a
difference in quality of life.
Participants had four study visits: the first one to provide informed
consent and be checked for eligibility, a second one a few weeks later
for randomisation, followed by visits six and twelve months later (end
of study).
2.3. Randomisation, masking, and study drugs
We randomised all eligible and willing patients in a 1:1 ratio to
either continuing treatment with vitamin K antagonists, or switching to
a direct oral anticoagulant. Randomisation was performed using an
interactive computer system provided by the hospital's trial coordina-
tion centre, without stratification. Blocks of 4 and 6 were used in
random order. Patients were unblinded for their allocated treatment to
allow proper assessment of quality of life.
Treatment with VKA was continued as usual. The time between INR
monitoring visits was based on the INR and was 6 weeks at most.
Treatment with DOAC was started following local guidelines. Most
patients received twice-daily apixaban; one patient received rivarox-
aban because of concurrent use of diltiazem.
2.4. Study outcomes
The primary outcomes of the GAInN study were clinical events and
have been described elsewhere [7]. The secondary outcome was quality
of life. We assessed general health-related and anticoagulation-related
quality of life, using the Medical Outcomes Study Short-Form 36 (SF-
36) [8] and Perception of Anticoagulant Treatment Questionnaire
(PACT-Q) [9]. Patients filled in the questionnaires before randomisa-
tion and during the research visits six and twelve months later.
The PACT-Q consists of two parts. The first part assesses treatment
expectations for new patients. Because all our patients were, by defi-
nition, experienced users, we did not administer this part of the ques-
tionnaire. The second part consists of eleven questions about con-
venience, two about burden of disease and treatment, and seven about
satisfaction. All questions were scored on a five-point Likert scale. The
answers to the questions about satisfaction were summed and rescaled
from 0 to 100 to produce the satisfaction scale. The responses to the
questions about convenience and burden of disease and treatment were
combined to produce the convenience scale [9]: first, the answers were
inverted, then summed, and then rescaled from 0 to 100. A higher score
indicates higher satisfaction or higher convenience.
The SF-36 is scored to obtain eight scales, and two summary com-
ponent scores: physical functioning, role physical, bodily pain, general
health, vitality, social functioning, role emotional and mental health,
and the physical and mental component scores. The physical and
mental components scores were determined by norming on a Dutch
population [10], using weights from the United States of America [11]
because data from the Netherlands are not available. A priori we con-
sidered it unlikely that anticoagulants would have an effect on the
scales for bodily pain, physical functioning, role emotional and role
physical. However, the SF-36 needs to be administered in full. We chose
not to postulate hypotheses for these subscales, and will not analyse
differences from baseline for these subscales.
We assessed overall treatment satisfaction highlighting one item in
the PACT-Q questionnaire: “Overall, how satisfied are you with your
anticoagulant treatment?” The answer to this question is on a five-point
(Likert) scale. For the baseline value, the answer to this question at the
time before randomisation was used. For development during the study,
we also looked at whether a patient decided to switch from their allo-
cated treatment to the other treatment (e.g. because of side-effects). If
that was the case, the answer to the treatment satisfaction question
could no longer be unambiguously interpreted. We then interpreted the
switch as a sign that the patient was less satisfied with the allocated
treatment. If the patient was still on the allocated treatment when (s)he
filled in the questionnaire, we used the answer to the question.
2.5. Statistical analysis
We calculated differences from baseline for every subject for all
quality of life outcomes. We assessed between-group differences using
an independent t-test or Mann-Whitney U test, as appropriate.
We assessed an individual's probability to obtain a relevant im-
provement or decline in quality of life. We considered a change of 5/
100 or less irrelevant; an improvement of> 5 was considered a re-
levant improvement, a decline of> 5 a relevant decline. This a priori
set threshold was chosen arbitrarily: there is no consensus about a cut-
off for relevance. We calculated absolute risk differences (ARD) for a
relevant improvement or relevant decline on all PACT-Q scores, the SF-
36 component scores, and the SF-36 scales for which an effect was not a
priori unlikely (see above). All changes in the 5-point scale of treatment
satisfaction were considered relevant. In addition, a switch based on
patient preference, side effects, or clinical events was considered a re-
levant decline.
If subjects scored ≥95/100 on a particular scale at baseline, they
could not experience a relevant improvement. As a sensitivity analysis,
we re-assessed absolute risk differences in the group of patients who did
not score ≥ 95/100 at baseline.
All analyses were performed in the intention-to-treat group, using R
version 3.6.1 (2019-07-05) (R Foundation for Statistical Computing,
Vienna, Austria). Data are reported as mean ± standard deviation or
median (interquartile range), as appropriate.
J.H.A. van Miert, et al. Thrombosis Research 190 (2020) 69–75
70
3. Results
3.1. Patient flow and follow-up
The flow of participants is outlined in Fig. 1. 5502 patients were
randomly selected and contacted by the Thrombosis Service. Between
January 13, 2015, and November 1, 2016, 241 patients provided in-
formed consent and were enrolled in the study. 121 patients were
randomly assigned to DOAC treatment; 120 were assigned to VKA. All
randomised patients started their allocated treatment; all of them were
included in the analysis. The study was closed when the last patient
completed the one-year follow-up on October 17, 2017. Median follow-
up time was 364 (362–369) days, leading to 240 patient-years of
follow-up.
The included patients were comparable with the selected eligible
patients in age (mean 72.3 versus 72.8 years), but were more likely to
be male (75.9% versus 67.3%).
3.2. Baseline characteristics
Baseline characteristics are summarised in Table 1. The mean age
was 72 ± 6.9 (range 46–91). 76% was male. The majority of partici-
pants had comorbidities, with hypertension (75%) being the most
common. Fewer subjects reported a stroke before starting VKA (10%) or
vascular disease (22%). Beta-blockers were prescribed in 65% of par-
ticipants; 13% used digoxin. Almost all patients were treated with
acenocoumarol, reflecting local preference. In both groups, there was 1
patient who used phenprocoumon at randomisation.
3.3. Quality of life
Quality of Life scores are summarised in Table 2. Before randomi-
sation, patients were very content with their treatment. Patients rated
their overall treatment satisfaction on average 4.2 ± 0.8 out of 5. 79
(65.3%) patients gave the maximum rating of 5. The PACT-Q treatment
satisfaction score was lower: median [IQR] 64 [57–71] out of 100.
Patients found their treatment very convenient (PACT-Q convenience
scale 98 [92–100], with 156 (64.7%) patients scoring ≥95/100). The
relevant SF-36 scales were well-balanced between the two groups.
Scores on a priori irrelevant SF-36 scales are reported in Supplementary
Table 1.
In general, the relevant health-related quality of life scores re-
mained constant during follow-up (Table 2) and changes during follow-
up were the same in both groups. Social functioning was an exception:
its score decreased over time in both groups. When excluding the 115
patients with a score of ≥95/100 at baseline, scores on social func-
tioning remained constant. After one year of follow-up, more patients
on DOAC than on VKA said their health was “somewhat” or “much
better” than at the start of the study: 24 versus 12 (absolute risk dif-
ference 10% (95% CI 1 to 19)). A similar number of patients reported
“somewhat” or “much” worse health compared with one year earlier:
17 versus 19 (ARD -2% (95% CI -11 to 7)).
Fig. 1. Patient flow in this study.
Table 1
Patient characteristics.
DOAC (n = 121) VKA (n = 120)
Age (years) - mean (SD) 73.1 ± 7.5 71.5 ± 6.1
Sex female - n (%) 29 (24%) 29 (24%)
Body mass index (kg/m2) - mean (SD) 28.3 ± 4.6 28.4 ± 4.7
CHA2DS2-VASc - median [IQR] 3.0 [2.0–4.0] 3.0 [2.0–4.0]
Prior stroke - n (%) 12 (10%) 11 (9%)
Heart failure - n (%) 34 (28%) 25 (21%)
Hypertension - n (%) 92 (76%) 89 (74%)
Diabetes mellitus - n (%) 25 (21%) 29 (24%)
Vascular disease - n (%) 28 (23%) 25 (21%)
Betablocker use - n (%) 79 (65%) 77 (64%)
Digoxin use - n (%) 20 (17%) 11 (9%)
Platelet aggregation inhibitor - n (%) 3 (2%) 9 (8%)
Non-steroidal anti-inflammatory agent - n
(%)
5 (4%) 3 (2%)
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Patients on DOAC reported an average increase in convenience,
compared with VKA: a difference of 1.8 (0.3–3.3) after six months. This
effect persisted after one year: 2.5 (0.3–4.7). In 156 patients who did
not score ≥ 95/100 at baseline the difference between DOAC and VKA
was more pronounced: 5.1 (1.7–8.4) after six months and 5.3 (1.8–8.9)
after one year, versus 0.3 (−0.6 to 1.2) and 1.4 (−1.3 to 4.0) in pa-
tients with a baseline convenience score ≥ 95/100. The average PACT-
Q Satisfaction score initially improved as well, but this effect was not
significant (3.3 (−1.4 to 8.1)) and the difference shrank after one year
(1.6 (−3.3 to 6.5)).
Patients on DOAC were more likely than patients on VKA to im-
prove>5 points on PACT-Q convenience, during six months of follow-
up: their probability was 11% (95% CI 2 to 21) higher than for patients
on VKA (Fig. 2). After one year of follow-up, this difference had
diminished: patients on DOAC then only had a 6% (95% CI -4 to 16)
higher probability to improve (Fig. 3), which was no longer significant.
The likelihood to experience a decline was the same in both groups,
with a difference in probabilities of −2% (95% CI -8 to 4) after six
months and 0% (95% CI -7 to 8) after one year. Likewise, patients on
DOAC were more likely to improve on PACT-Q satisfaction at six
months, but no longer after one year, as illustrated in Figs. 2 and 3. The
probability to decline was similar on VKA and DOAC.
We found no differences in probabilities to improve or decline on
the SF-36 scales after either six months or one year.
Patients on DOAC were more likely to experience an improvement
in general treatment satisfaction (the probability was 10% (95% CI -1 to
20) higher than on VKA after six months), yet also more likely to ex-
perience a decline or reason to switch (difference in probabilities 8%
Table 2
General health-related, and anticoagulation related quality of life.
Scale Baseline Change after six months Change after one year
DOAC VKA DOAC VKA p DOAC VKA p
Full study population
PACT-Q convenience 98 [92–100] 96 [92–99] 2.6 ± 6.9 0.8 ± 4.2 0.02 2.4 ± 7.4 −0.1 ± 9.7 0.03
PACT-Q satisfaction 64 [57–71] 64 [57–71] 4.7 ± 19.2 1.4 ± 16.9 0.17 3.9 ± 18.7 2.3 ± 18.9 0.51
General Health 67 [52–77] 62 [52–77] −0.9 ± 13.3 1.3 ± 13.4 0.22 −1.0 ± 13.2 0.5 ± 14.0 0.41
Vitality 70 [55–80] 75 [65–85] −0.4 ± 14.3 −2.3 ± 11.9 0.29 −0.6 ± 12.3 −1.8 ± 13.1 0.49
Social Functioning 88 [75–100] 88 [75–100] −2.4 ± 18.0 −2.8 ± 15.8 0.85 −4.1 ± 15.9 −3.2 ± 17.5 0.68
Mental Health 82 [72–92] 84 [76–92] −0.3 ± 13.3 −1.7 ± 12.4 0.42 0.1 ± 10.9 0.1 ± 10.1 0.96
SF-36 Physical component 47 [40–52] 51 [44–54] −0.7 ± 7.0 −0.6 ± 6.9 0.87 −0.6 ± 6.7 −1.6 ± 7.1 0.28
SF-36 Mental component 55 [49–58] 55 [49–58] 0.0 ± 8.2 −0.8 ± 6.9 0.45 0.0 ± 6.7 0.1 ± 7.2 0.94
Subgroup with baseline score < 95
PACT-Q convenience 88 [80–92] 90 [88–92] 7.9 ± 9.3 2.9 ± 5.2 0.004 8.4 ± 9.4 3.1 ± 6.1 0.004
Social Functioning 75 [62–88] 88 [62–88] 3.6 ± 18.3 0.9 ± 16.8 0.40 −0.6 ± 18.2 −0.8 ± 21.9 0.95
Values are given as median [IQR] or mean ± SD as appropriate.
Ps from unpaired t-tests. No Ps are given for baseline, because the subjects were randomised. No hypothesis testing was performed for scales that are unlikely to be
affected by anticoagulants.
Abbreviations: DOAC, direct oral anticoagulant; VKA, vitamin K antagonist.
Fig. 2. Quality of life after six months.
Difference in proportions of patients experiencing a relevant decline resp. improvement on a direct oral anticoagulant, compared with a vitamin K antagonist, after
six months of follow-up.
Items marked with * exclude subjects with a score of ≥95/100 or 5/5 at baseline.
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(95% CI -2 to 18)). After one year, the probability to improve was 5%
(95% CI -6 to 16) higher on DOAC, and the probability to decline or
switch was 8% (95% CI -2 to 18) higher than on VKA.
In another analysis, we only included patients who could actually
improve, because they scored<95/100 or < 5/5 at baseline. They
were even more likely to increase in PACT-Q convenience under DOAC
(as indicated by the asterisk in Figs. 2 and 3). Although the effect at-
tenuated after one year in this group as well, it remained significant.
The subgroup of patients who were not fully satisfied with their treat-
ment at baseline was far more likely to increase in overall satisfaction
after the switch to a DOAC: the probability was 18% (95% CI 4 to 33)
higher than that on VKA after six months. In contrast to the overall
group, the probability to decline was not higher on DOAC: the differ-
ence was −1% (95% CI -10 to 8) after six months. After one year of
follow-up, patients remained more likely to improve (difference 13%
(95% CI -2 to 28)) and less likely to decline (difference 4% (95% CI -5 to
13)) than the complete population, but the differences diminished and
were no longer statistically significant.
At the end of the study, DOAC patients could choose whether to
continue DOAC or switch back to VKA. Out of the 121 patients ran-
domised to DOAC, 105 (86.8%) chose to continue their DOAC. 12
(9.9%) had switched back to VKA during the study (mainly over per-
ceived side-effects: one developed another indication for VKA; two had
an event under DOAC). 2 (1.7%) patients had died. 2 (1.7%) patients
preferred to switch back to VKA at the end of the study (mainly because
of the higher out-of-pocket expense of DOAC).
4. Discussion
In patients who were well-controlled on VKA, we found that
switching to a DOAC only marginally improved average treatment
convenience and did not affect other parameters of quality of life. On
the individual level, a minority of patients experienced a “relevant
improvement” of> 5 points on anticoagulation-related, but not gen-
eral, quality of life. However, the effect of a switch to a DOAC was not
just positive: the number of patients who were more satisfied overall
was the same as the number of patients who were less satisfied or
decided to switch back to a VKA. Only in the subgroup of patients who
were not fully satisfied at baseline did the DOAC cause more patients to
improve than to decline or switch.
Our study is the first to focus exclusively on patients who were well-
controlled on VKA at baseline. Our findings are in line with results from
the RE-LY trial [12], where no differences were found in quality of life
between patients randomised to dabigatran or warfarin. Other studies
assessed quality of life outside a randomised controlled setting. This
makes results more difficult to interpret, as patients with lower
thrombotic and bleedings risks are switched more often [13]. Differ-
ences in clinical characteristics can confound the relationship between
prescribed anticoagulant and quality of life scores. One study accounted
for this with propensity score matching and found no difference in
quality of life between DOAC and VKA [14]. Another study used re-
gression analysis to correct for confounders and found that patients on
DOAC experienced less burden and more benefit from treatment [15].
Other studies that report a higher quality of life on DOAC should be
interpreted with caution, because they did not address baseline differ-
ences [16,17].
Our study benefits from randomisation while maintaining a design
that closely resembles “real-life”. Patients randomised to DOAC had no
appointments at the anticoagulation clinic, except for a study visit at six
months and one year. This allowed them to experience the absence of
INR monitoring visits (which was impossible in the registration trials)
and associated reassurance. A potential limitation of the randomised
setting is the generalisability: patients with a strong preference to
continue VKA have not been included in the study. However, these
patients would not be switched with current shared decision making
either. Enrolled subjects were representative of the identified patients
in age but slightly more often male. Because this study was a pilot study
aimed at clinical events, we did not perform a sample size calculation
for quality of life outcomes. In our study, we adopted an arbitrary cutoff
of more than five points. Most analyses have been performed according
Fig. 3. Quality of life after one year.
Difference in proportions of patients experiencing a relevant decline resp. improvement on a direct oral anticoagulant, compared with a vitamin K antagonist, after
1 year of follow-up.
Items marked with * exclude subjects with a score of ≥95/100 or 5/5 at baseline.
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to the intention-to-treat principle: patients who discontinued their al-
located treatment were analysed in their allocated group. Theoretically,
the switch away from the allocated treatment could lead to an im-
provement in quality of life (e.g. when a patient no longer suffered side-
effects); if this were attributed to the allocated treatment this could
distort the results. This effect would be strongest on the single question
about general treatment satisfaction. We therefore took switching into
account for this question; for the other questions we maintained the
intention-to-treat principle. However, results in the per-protocol ana-
lyses were not meaningfully different, making this distortion unlikely.
Symptoms of AF, such as palpitations and dyspnoea, also affect quality
of life [18]. We have not assessed symptom severity but an effect of
anticoagulation on AF symptoms is pathophysiologically implausible.
Furthermore, we have excluded SF-36 scales most sensitive to AF
symptoms.
Overall, patients in our study already scored high on treatment
convenience at baseline. These patients were selected because they had
a high TTR, which allows for more time between INR monitoring. This
lowers treatment burden [19] and increases convenience [4]. Further-
more, they are less likely to suffer from bleeding and thrombotic events
than patients with a poor TTR [6]. Another explanation for the high
convenience would be that these patients are managed by a well-or-
ganised, dedicated, anticoagulation clinic with wide opening hours.
Patients from this clinic expressed high convenience before [4].
With treatment convenience already so high, switching to a DOAC
could not make much of a difference. Indeed, an increase in con-
venience was confined to patients who scored<95 on convenience at
baseline (the difference was 5.3 (1.8–8.9) points relative to VKA, versus
1.4 (−1.3 to 4.0) in patients who scored ≥95 at baseline). Of these
patients, 1 additional patient out of every 4.6 (95% CI 2.3–140.5) who
switched experienced a relevant increase in convenience. A possible
explanation is that patients prefer taking a fixed dose of 1 tablet of
apixaban twice daily, compared with multiple and a variable number of
tablets for acenocoumarol once daily.
Furthermore, switching to a DOAC did not result in a meaningful
difference on other measures of quality of life. Nevertheless, the ma-
jority of patients on DOAC preferred to continue their DOAC at the end
of the study, instead of switching back to VKA. This could indicate that
patients favour DOAC over VKA, despite the only small difference in
anticoagulation-related quality of life.
Another explanation, however, for their preference to continue
DOAC could be that patients dread drug changes when they do not
expect much benefit. This could also explain the low participation rate
in our study. 5 (4.1%) patients on DOAC experienced side-effects; an
additional 4 (3.3%) patients had another reason why they wanted to
resume VKA therapy. This effect negated the positive effects on general
treatment satisfaction that other patients experienced.
However, even if switching to a DOAC would have no positive effect
on quality of life, switching could still be justified if it would lead to
better clinical outcomes. In this study, we hypothesised that well-con-
trolled patients on VKA would actually be harmed by switching to a
DOAC. However, we found no evidence to support this hypothesis:
clinical endpoints were distributed evenly between the two groups [7].
In a more general study population, DOACs lead to a reduced risk of
intracranial haemorrhage and ischaemic stroke, although the absolute
risk reductions are modest [5]. Although well-controlled patients who
find VKA therapy inconvenient have more to gain by switching to a
DOAC, we believe all patients should be counselled about the different
options available for stroke prevention in AF. This study can be helpful
in shared decision making and weighing a possible improvement in
treatment convenience against the risk of side-effects.
5. Conclusion
In a population with good VKA control, a switch to a DOAC has no
effect on general health-related quality of life, but leads to a small
increase in anticoagulation-related quality of life. However, the switch
introduced side-effects and other reasons patients decided to resume
VKA therapy. These should be considered before switching from well-
controlled VKA to a DOAC. Patients who are not satisfied with treat-
ment with VKA have more to gain by switching to a DOAC. Physicians
and their patients should together weigh the advantages and dis-
advantages.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.thromres.2020.04.007.
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